August 20, 2020 7:33pm

Pre-open indication results: 5 HITs and 5 MISS

The Biostage *BSTG) Chronicles: keep “pumping” the stock, it’s dollars less that go to the operations of the company

An “intelligence newspaper” for smart investing in the RegMed, gene and cell therapy sector.  I say today what others won't, so you can do what others can't.

Subscription is coming, my gift to you, I've kept RMi subscription FREE during these COVID-19 and volatile times!

The Dow closed UP +46.85 points (+0.17%), the S&P closed UP +10.66 points (+0.32%) while the NASDAQ closed UP +118.49 points (+1.06%)

 

Pre-open indication results: 5 HITs < Mesoblast (MESO -$0.12), CRISPR Therapeutics (CRSP-$8.13), Pluristem (PSTI -$0.24), uniQure NV (QURE -$0.69), Ionis Pharmaceuticals (IONS +$0.77) and 5 MISS  < Biostage (BSTG +$0.16), Vericel (VCEL +$0.29), Alnylam Pharmaceuticals (ALNY -$0.86), bluebird bio (BLUE -$1.82), Sangamo Therapeutics (SGMO -$0.56)

 

Henry’omics:

Indexes rose moderately on Thursday as broad gains in major tech names served as a counterweight to disappointing unemployment data.

First-time jobless claims in the U.S. moved back above 1 million after dipping below that mark a week earlier as businesses continue to struggle bringing workers back on the job amid the pandemic.

This a.m. I stated in this a.m.’s newsletter – RegMed Investors’ (RMi) pre-open: volatility is chewing on the sector resulting in oversold conditions in some … https://www.regmedinvestors.com/articles/11510.

Continue to get a “grip” on your portfolio, the worst isn’t over …

 

RegMed/Cell and Gene therapy 35 covered equities’ Advance/Decline (A/D) lines: progressions and regressions …

  • Thursday opened negative at 16/18 and 1 flat, stayed negative at the mid-day at 11/22 and 2 flats, closing negative at 12/22 and 1 flat;
  • Wednesday opened negative at 12/20 and 3 flats, strayed positive at the mid-day at 17/14 and 4 flats, closing negative at 16/17 and 2 flats;
  • Tuesday opened negative at 8/26 and 1 flat, stayed negative at the mid-day at 9/24 and 2 flats, closing negative at 13/20 and 2 flats;
  • Monday opened positive at 27/7 and 1 flat, stayed positive at the mid-day at 29/4 and 2 flats, closing positive at 29/4 and 2 flats;

 

Key metrics:

  • Sector volume was LOW with 4 of the 12-upside having higher than the 3-month average volume and the 5 of 22-downside having higher than the 3-month average volume;
  • Thursday’s percentage (%) of the 12-upside were +0.02% (RARE) to +13.68% (BSTG) while the 22-downside ranges from -0.36% (AGTC) to -8.82% (CRSP); 

 

Hammered in today’s market:

  • CRISPR Therapeutics (CRSP), ReNeuron (RENE.L), bluebird bio (BLUE), Alnylam Pharmaceuticals (ALNY), uniQure NV (QURE) to name 5 of the 22 declining of the 35 covered

Jumping with share pricing momentum:

  • Ionis Pharmaceuticals (IONS), Global Blood Therapeutics (GBT), Precigen (PGEN), Vericel (VCEL), BioLife Solutions (BLFS) to name 5 of the 12 trading up of 35 covered

 

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Thursday, the IBB closed down -0.30% and XBI also closed down -0.02%
  • Wednesday, the IBB closed down -1.06% and XBI also closed down -0.17%
  • Tuesday, the IBB closed down -0.57% and XBI also closed down -0.88%
  • Monday, the IBB closed up +1.97% and XBI also closed up +3.50%

 

Thursday’s (12 of 12) incliners:

  • Ionis Pharmaceuticals (IONS +$0.77 after Wednesday’s -$1.37, Tuesday’s -$0.34 and Monday’s +$1.21);
  • Global Blood Therapeutics (GBT +$0.49 after Wednesday’s +$0.63, Tuesday’s -$0.48 and Monday’s +$3.43);
  • Precigen (PGEN +$0.29 after Wednesday’s +$0.39);
  • Vericel (VCEL +$0.26 after Wednesday’s +$0.28 and Tuesday’s +$0.15);
  • BioLife Solutions (BLFS +$0.20);
  • Biostage (BSTG +$0.16);
  • Adverum Biotechnologies (ADVM +$0.14 after Wednesday’s -$0.52);
  • Fate Therapeutics (FATE +$0.13 after Wednesday’s +$0.34 and Tuesday’s +$0.34);
  • Homology Medicine (FIXX +$0.09 after Wednesday’s-$0.35 and Tuesday’s -$0.35);
  • Aduro Biotech (ADRO +$0.075 after Wednesday’s +$0.16 and Tuesday’s +$0.30);
  • Sage Therapeutics (SAGE +$0.04);
  • Ultragenyx (RARE +$0.02);

Thursday’s (10 of 22) decliners:

  • CRISPR Therapeutics (CRSP -$8.88 after Wednesday’s +$5.72, Tuesday’s +$3.27 and Monday’s +$2.15);
  • ReNeuron (RENE.L -$5.00);
  • bluebird bio (BLUE -$1.82 after Wednesday’s -$0.90, Tuesday’s -$0.41 and Monday’s +$2.59);
  • Alnylam Pharmaceuticals (ALNY -$0.86 after Wednesday’s -$2.70, Tuesday’s -$0.78 and Monday’s +$4.56);
  • uniQure NV (QURE -$0.72 after Wednesday’s -$2.04);
  • Brainstorm Cell Therapeutics (BCLI -$0.68 after Wednesday’s -$0.43, Tuesday’s -$0.53 and Monday’s +$1.12);
  • Intellia Therapeutics (NTLA -$0.60);
  • Cellectis SA (CLLS -$0.58 after Wednesday’s +$1.14, Tuesday’s +$0.74);
  • Sangamo Therapeutics (SGMO -$0.56 after Wednesday’s +$0.32 and Tuesday’s +$0.21):
  • Regenxbio (RGNX -$0.56 after Wednesday’s -$2.43);

Closing flat: 1 –Stemline Therapeutics (STML – acquired)

 

Percentage (%) movement/range statistics: comparisons

  • Thursday’s percentage (%) of the 12-upside were +0.02% (RARE) to +13.68% (BSTG) while the 22-downside ranges from -0.36% (AGTC) to -8.82% (CRSP);  
  • Wednesday’s percentage (%) of the 16-upside were +0.05% (RARE) to +10.89% (PSTI) while the 17-downside ranges from -0.51% (EDIT) to -13.33% (BSTG); 
  • Tuesday’s percentage (%) of the 13-upside were +0.03% (RGNX) to +13.81% (SLDB) while the 20-downside ranges from -0.41% (PSTI) to -37.50% (BSTG); 
  • Monday’s percentage (%) of the 29-upside were +0.58% (CLLS) to +13.26% (PGEN) while the 4-downside ranges from -1.82 (BSTG) to -3.05% (BLCM); 

 

Sentiment and a few daily indicators:

The jump in unemployment claims came as lawmakers struggled to move forward on a new coronavirus stimulus bill.

  • Thursday 5.54 cases
  • Wednesday 5.48 cases
  • Tuesday 5.45 cases
  • Monday 5.4 cases

Thursday’s day’s death rate totaled 173,600 after Wednesday’s 172,418, Tuesday’s 171,013 and Monday’s 170,000, <Johns Hopkins University>

 

Stats:

Upside volume: 

  • Thursday: 4 out of the 12-upside had higher than the 3-month average volume;
  • Wednesday: 5 out of the 16-upside had higher than the 3-month average volume;
  • Tuesday: 2 out of the 13-upside had higher than the 3-month average volume;
  • Monday: 5 out of the 29-upside had higher than the 3-month average volume;

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Thursday was up +0.18 points or +0.80% at 22.72
  • Wednesday was up +1.03 points or +4.79% at 22.54
  • Tuesday was up +0.16 points or +0.75% at 21.51
  • Monday was down -0.70 points or -3.17% at 21.35

Downside volume:

  • Thursday: 15 out of the 22-downside had higher than the 3-month average volume;
  • Wednesday: 5 out of the 17-downside had higher than the 3-month average volume;
  • Tuesday: 3 out of the 20-downside had higher than the 3-month average volume;
  • Monday: 2 out of the 4-downside had higher than the 3-month average volume;

 

August, the second month of Q3 …

Thursday closed negative with 12 advancers, 22 decline and  flat

Wednesday closed negative with 16 advancers, 17 declines and 2 flats

Tuesday closed negative with 13 advancers, 20 declines and 2 flats

Monday (8/17) closed positive with 29 advancers, 4 declines and 2 flats

Friday closed negative with 10 advancers, 23 decline and 2 flats

Thursday closed positive with 19 advancers, 11 decline and 4 flats

Wednesday closed negative with 13 advancers, 19 declines and 3 flats

Tuesday closed negative with 3 advancers, 32 declines and 1 flat

Monday (8/10) closed positive with 25 advancers, 8 declines and 2 flats

Friday closed positive with 21 advancers, 11 declines and 3 flats

Wednesday closed positive with 19 advancers, 15 declines and 1 flat

Tuesday closed negative with 13 advancers, 20 declines and 2 flats

Monday (8/3) closed positive with 31 advancers, 1 decline and 3 flats

 

The Bottom line:  As I had stated, sector investors should be prepared for more profit-taking.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.